What the FDA labels say about taking them together
Axitinib and bosentan
Axitinib's FDA label of March 12, 2026 names bosentan in its drug interactions section; the bosentan label PlainMeds reads does not name axitinib. The axitinib label: “Moderate CYP3A4/5 inducers may also reduce the plasma exposure of axitinib and should be avoided if possible.”
Check it at the source: the axitinib FDA label on DailyMed (effective March 12, 2026, U.S. Pharmaceuticals); the bosentan FDA label on DailyMed (effective November 17, 2025, Actelion Pharmaceuticals US, Inc.).
What does the axitinib label say about bosentan?
Axitinib label, drug interactionsModerate CYP3A4/5 inducers (e.g., bosentan, efavirenz, etravirine, modafinil, and nafcillin) may also reduce the plasma exposure of axitinib and should be avoided if possible.
Source: FDA drug label (INLYTA), NDA202324 (Pf Prism Cv), as published by U.S. Pharmaceuticals, effective March 12, 2026 (SPL set 8a903e31-936e-4ed7-8a59-59f32374f338), via openFDA; the full label on DailyMed
What does the bosentan label say about axitinib?
Bosentan's label (effective November 17, 2025) does not name axitinib in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Tracleer), Actelion Pharmaceuticals US, Inc., effective November 17, 2025 (SPL set 749e42fb-2fe0-45dd-9268-b43bb3f4081c), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Axitinib | Bosentan | |
|---|---|---|
| Labeled for | n/a | Pulmonary arterial hypertension |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once